BioCentury | Feb 1, 2020
Distillery Therapeutics

CDK7 inhibition for treating small cell lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting CDK7, a cell cycle regulator, could treat small cell lung cancer (SCLC) and enhance the efficacy of checkpoint inhibition and chemotherapy. In mouse and human SCLC cell lines,...
BC Extra | Oct 17, 2019
Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

After tolerability issues in a Phase I trial led to lower doses and longer infusion times for its first clinical CDK7 inhibitor, Syros is choosing to concentrate instead on a preclinical oral compound aimed at...
BC Innovations | Aug 8, 2019
Distillery Therapeutics

CDK7 inhibition for drug-resistant cancers

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma; solid tumors Inhibiting CDK7 could treat hedgehog signaling-driven cancers resistant to SMO inhibitors. A CDK7 inhibitor tool compound decreased viability of cells resistant to SMO inhibitors and driven...
BC Innovations | Dec 4, 2018
Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies identified a CDK7/CDK12/CDK13 inhibitor that could help treat ovarian cancer. Screening of 42 small molecules targeting transcriptional and/or epigenetic components in two human ovarian cancer cell lines...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Extra | Dec 21, 2017
Preclinical News

New pathway could overcome resistance to TKIs in cancer

In a paper published in Cancer Research , researchers at Dana-Farber Cancer Institute and colleagues discovered that the recently identified ufmylation pathway plays a role in resistance to tyrosine kinase inhibitors (TKIs), and suggested that promoting...
BC Innovations | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
BC Innovations | Oct 10, 2017
Distillery Therapeutics

Cancer

INDICATION: Nasopharyngeal cancer Cell culture and mouse studies identified inhibitors of CDK7 that could help treat nasopharyngeal cancer (NPC). A screen of 126 small molecules identified three known inhibitors CDK7 that inhibited proliferation of seven...
BioCentury | May 6, 2017
Product Development

Finding gems in India

For Agios Pharmaceuticals Inc. , the decision to license molecules from Indian CRO Aurigene Discovery Technologies Ltd. was a special case intended to save time getting a new project off the ground, rather than part of...
BC Innovations | May 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting BRD4 or CDK7 could help treat diffuse intrinsic pontine glioma (DIPG). In DIPG cells from eight patients, a bromodomain inhibitor tool compound or a CDK7...
Items per page:
1 - 10 of 33